Patent · US Active

Antigenic GM-CSF peptides and antibodies to GM-CSF

US8623364B2 · kind B2 · utility

8Cited by
19References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 24, 2012
Grant dateJan 7, 2014
Priority date
Expiry dateOct 24, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.